Oct 3 |
Larimar started at outperform by Wedbush on FA drug candidate
|
Sep 19 |
Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research
|
Sep 12 |
Jones Research starts Larimar at Buy, cites lead asset nomlabofusp
|
Aug 27 |
Larimar Therapeutics to Participate in Upcoming Investor Conferences
|
Aug 7 |
Larimar Therapeutics GAAP EPS of -$0.34
|
Aug 7 |
Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results
|
Jul 30 |
Bullish Larimar Therapeutics Insiders Loaded Up On US$540.7k Of Stock
|
Jul 15 |
Larimar Therapeutics: More Data Still Needed
|
May 31 |
Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed
|
May 30 |
Larimar's Friedreich's ataxia asset nomlabofusp chosen for FDA accelerated program
|